hrcak mascot   Srce   HID

Review article

HOW TO IMPROVE PERIOPERATIVE BLOOD MANAGEMENT IN PATIENTS UNDERGOING TOTAL HIP OR KNEE REPLACEMENT SURGERY?

Dagmar Oberhofer
Kata Šakić
Saša Janković
Dinko Tonković
Goran Vrgoč

Fulltext: croatian, pdf (215 KB) pages 0-0 downloads: 187* cite
APA 6th Edition
Oberhofer, D., Šakić, K., Janković, S., Tonković, D. & Vrgoč, G. (2012). KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?. Liječnički vjesnik, 134 (11-12), 0-0. Retrieved from https://hrcak.srce.hr/172453
MLA 8th Edition
Oberhofer, Dagmar, et al. "KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?." Liječnički vjesnik, vol. 134, no. 11-12, 2012, pp. 0-0. https://hrcak.srce.hr/172453. Accessed 25 Feb. 2020.
Chicago 17th Edition
Oberhofer, Dagmar, Kata Šakić, Saša Janković, Dinko Tonković and Goran Vrgoč. "KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?." Liječnički vjesnik 134, no. 11-12 (2012): 0-0. https://hrcak.srce.hr/172453
Harvard
Oberhofer, D., et al. (2012). 'KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?', Liječnički vjesnik, 134(11-12), pp. 0-0. Available at: https://hrcak.srce.hr/172453 (Accessed 25 February 2020)
Vancouver
Oberhofer D, Šakić K, Janković S, Tonković D, Vrgoč G. KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?. Liječnički vjesnik [Internet]. 2012 [cited 2020 February 25];134(11-12):0-0. Available from: https://hrcak.srce.hr/172453
IEEE
D. Oberhofer, K. Šakić, S. Janković, D. Tonković and G. Vrgoč, "KAKO POBOLJŠATI TRANSFUZIJSKO LIJEČENJE BOLESNIKA PODVRGNUTIH UGRADNJI TOTALNIH ENDOPROTEZA KUKA I KOLJENA?", Liječnički vjesnik, vol.134, no. 11-12, pp. 0-0, 2012. [Online]. Available: https://hrcak.srce.hr/172453. [Accessed: 25 February 2020]

Abstracts
Total hip and knee arthroplasty is associated with significant perioperative blood loss, necessitating often blood transfusions. Because of risks and cost of allogenic blood transfusion and elective types of surgery several alternative methods have been developed to reduce allogenic blood use. We prospectively audited 65 consecutive patients undergoing primary total hip (THR; n=30) or knee replacement (TKR; n=35) at our Department of Orthopaedic Surgery which did not use autologous blood collection methods. Total blood loss in THR (1329.7±364.8 ml) and TKR (1427.3±660.4 ml) was similar to previously reported and without significant difference between the groups. However, we reported high transfusion rates with 63.3% of THR and 82.6% of TKR patients receiving allogenic blood. Important steps to reduce allogenic blood use would include implementation of restrictive transfusion protocols with a defined hemoglobin value as a transfusion trigger, correction of preoperative anemia with i.v. iron ± erythropoietin, use of one or more modalities of autologous transfusion (postoperative autotransfusion, preoperative blood donation), pharmacological agents like tranexamic acid (anti-fibrinolytic) and other complementary procedures. There is sufficient evidence in literature about the cost-benefit of certain methods which makes routine use of allogenic blood in THR and TKR surgery unacceptable even at general orthopaedic surgery departments.

Keywords
Arthroplasty, replacement, hip; Arthroplasty, replacement, knee; Blood loss, surgical; Blood transfusion; Blood transfusion, autologous

Hrčak ID: 172453

URI
https://hrcak.srce.hr/172453

[croatian]

Visits: 366 *